Association of antibody titers against ALK with the presence and amount of circulating tumor cells
| . | All . | ALK-antibody titer patients (%) . | P . | ||
|---|---|---|---|---|---|
| 0-≤ 1/750 . | 1/2025-< 1/20 250 . | ≥ 1/60 750 . | |||
| BM-PCR* | < .001 | ||||
| Negative | 40 | 9 (43) | 10 (33) | 21 (84) | |
| Positive | 36 | 12 (57) | 20 (67) | 4 (16) | |
| PB-PCR* | .004 | ||||
| Negative | 26 | 6 (37) | 6 (25) | 14 (74) | |
| Positive | 33 | 10 (63) | 18 (75) | 5 (26) | |
| BM-quant† | .001 | ||||
| ≤ 10 NCN | 55 | 11 (61) | 19 (70) | 25 (100) | |
| > 10 NCN | 15 | 7 (39) | 8 (30) | 0 (0) | |
| PB-quant† | < .001 | ||||
| ≤ 10 NCN | 42 | 8 (50) | 15 (63) | 19 (100) | |
| > 10 NCN | 17 | 8 (50) | 9 (37) | 0 (0) | |
| . | All . | ALK-antibody titer patients (%) . | P . | ||
|---|---|---|---|---|---|
| 0-≤ 1/750 . | 1/2025-< 1/20 250 . | ≥ 1/60 750 . | |||
| BM-PCR* | < .001 | ||||
| Negative | 40 | 9 (43) | 10 (33) | 21 (84) | |
| Positive | 36 | 12 (57) | 20 (67) | 4 (16) | |
| PB-PCR* | .004 | ||||
| Negative | 26 | 6 (37) | 6 (25) | 14 (74) | |
| Positive | 33 | 10 (63) | 18 (75) | 5 (26) | |
| BM-quant† | .001 | ||||
| ≤ 10 NCN | 55 | 11 (61) | 19 (70) | 25 (100) | |
| > 10 NCN | 15 | 7 (39) | 8 (30) | 0 (0) | |
| PB-quant† | < .001 | ||||
| ≤ 10 NCN | 42 | 8 (50) | 15 (63) | 19 (100) | |
| > 10 NCN | 17 | 8 (50) | 9 (37) | 0 (0) | |
BM indicates bone marrow; and PB, peripheral blood.
Antibody titers against ALK and amount of circulating tumor cells in BM (76 patients) or PB (59 patients) measured by qualitative PCR for NPM-ALK.
Antibody titers and presence of circulating tumor cells in BM (70 patients) or PB (59 patients) measured by quantitative PCR for NPM-ALK.